Street Calls of the Week
TYLER, Texas - NanoVibronix, Inc. (NASDAQ:NAOV), a medical technology company focused on non-invasive therapeutic systems, announced Monday it has entered into a definitive agreement with an institutional investor to sell 291,204 shares of common stock at $7.01 per share in a registered direct offering. The company, currently valued at $6.7 million, has seen significant price volatility with an 87% surge in the past week, according to InvestingPro data.
The offering, priced at-the-market under Nasdaq rules, is expected to generate approximately $2 million in gross proceeds before deducting placement agent fees and other expenses. The transaction is anticipated to close on or about September 17, 2025, subject to customary closing conditions.
Palladium Capital Group, LLC is serving as the exclusive placement agent for the offering.
NanoVibronix plans to use the net proceeds for general working capital purposes, including repayment of certain outstanding debt and potential redemption of outstanding preferred stock.
The offering is being conducted pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on August 1, 2023, and declared effective on August 11, 2023.
NanoVibronix develops acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize low-intensity surface acoustic wave technology to treat pain and reduce bacterial colonization. The company also offers the ENvue Navigation Platform, an FDA-cleared electromagnetic navigation system for placing feeding tubes.
The information in this article is based on a company press release statement.
In other recent news, NanoVibronix, Inc. reported significant developments that may interest investors. The company announced that its subsidiary, ENvue Medical Holdings, has been granted two new U.S. patents. One patent, issued on September 9, 2025, covers an insertion device positioning guidance system, while another, issued on September 2, 2025, involves technology for overlaying electromagnetic navigation data onto real-time medical imaging. These advancements aim to enhance the accuracy and visualization of medical procedures. Additionally, NanoVibronix has filed a prospectus for the potential resale of up to 1,347,935 shares of common stock by selling stockholders, which includes shares issuable upon conversion of Series H Convertible Preferred Stock and exercise of warrants. The company also announced a 1-for-10 reverse stock split effective August 11, 2025. These recent developments reflect NanoVibronix’s ongoing efforts to expand its intellectual property and manage its stock structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.